« Zurück
Home /
Eltrombopag (Olamine)

Eltrombopag (Olamine)

ArtNr	HY-15306A-10mM
Hersteller	MedChem Express
CAS-Nr.	496775-62-3
Menge	10mM/1mL
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neuroinflammation Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Typ	Inhibitors
Specific against	other
Purity	99.96
Formula	C29H36N6O6
Citations	Eur J Clin Pharmacol. 2022 Aug 3.<br/>Front Pharmacol. 2020 Nov 16;11:582625.<br/>Alzheimers Res Ther. 2024 Jun 3;16(1):121.<br/>Blood Adv. 2017 Feb 28;1(7):468-476.<br/>BMC Cancer. 2020 Nov 30;20(1):1171.<br/>Cells. 2022, 11(3), 319.<br/>Curr Microbiol. 2021 Feb 21.<br/>J Pharm Biomed Anal. 235, 25 October 2023, 115683<br/>J Thromb Haemost. 2022 May 27.<br/>Virology. 2023 Jun 21.<br/>Viruses. 2019 Apr 25;11(4):385. <br/>[1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.<br/>[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.<br/>[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372.<br/>[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.<br/>[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702.
Smiles	O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Eltrombopag diethanolamine salt; SB-497115GR
Lieferbar
Product Description	Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	564.63
Clinical Information	Launched
Manufacturers Research Area	Cancer; Infection; Cardiovascular Disease
Solubility	DMSO : ≥ 50 mg/mL
Target	Apoptosis; Bacterial; Thrombopoietin Receptor
Manufacturers Target	Apoptosis; Bacterial; Thrombopoietin Receptor
Manufacturers Pathway	Anti-infection; Apoptosis; Immunology/Inflammation
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-15306A-10mM-safety-datasheet.pdf